About this trial
In patients with haemophilia, close monitoring of bleeding with optimal adherence to treatment, a personalised treatment programme and the possibility of early diagnosis of haemarthrosis are essential. The TEMPO project will help advance the state of the art in optimal adherence, rigorous monitoring, and accurate and early diagnosis and management of haemarthrosis by collecting and integrating big data in order to personalise the treatment regimen for each patient, as envisaged by the current model of personalised medicine.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
informed consent
age (minimum 18 years)
hemophilia
having a smartphone
Disqualifiers
autoimmune, inflammatory or degenerative diseases that cause arthritis
Trial design
Parallel
Treatments tested in this trial
TEMPO
Other interventionPersonalized telemedicine
Treatment groups
Trial outcomes
Primary outcomes
Veritas Pro score
Score for adherence to prophylactic treatment
Sponsors and contacts
Click on the lead sponsor to view all of their trials.